NMRA Neumora Therapeutics, Inc. Common Stock
Healthcare$1.84-0.54%ClosedMarket Cap: $340.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
4.71
P/S
0.00
EV/EBITDA
-0.89
DCF Value
$1.10
FCF Yield
-56.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-181.7%
ROA
-144.5%
ROIC
-179.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-52.9M | $-53.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-58.5M | $-59.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-241.2M | $-236.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-57.7M | $-56.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-54.0M | $-52.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-70.9M | $-68.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-62.9M | $-58.8M | $— | — |
| FY null | $0.00 | NaN% | $-263.5M | $-243.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-76.6M | $-72.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-63.8M | $-58.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-60.1M | $-53.7M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-50.1M | $-108.7M | $-0.68 | — |